rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

TherapeuticsMD, Inc.

TXMD · Nasdaq

Health CareBiotechnologyNot moving yet

TXMD stood above a rising 150-day average in 34 of the last 52 weekly readings, and has been out of that trend for the last 8 weeks. It is 8.4% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 8
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$14K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
43 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 34 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$14KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders43-2 on the quarter
New · exited5 · 7
Reported value$8.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Rubric Capital Management LPunchanged · filed 14 Aug 20261,192,191$2.6M00.0%
Clearline Capital LPunchanged · filed 14 Aug 2026635,222$1.4M00.0%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026353,697$782K00.0%
Tejara Capital Ltdreduced · filed 11 Aug 2026344,482$761K-1,370−0.4%
ADAR1 Capital Management, LLCadded · filed 14 Aug 2026342,447$757K+133,237+63.7%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026146,599$324K+399+0.3%
MORGAN STANLEYunchanged · filed 13 Aug 2026129,217$286K00.0%
BlackRock, Inc.unchanged · filed 7 Aug 2026115,145$254K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026105,849$234K-3,968−3.6%
CITADEL ADVISORS LLCadded · filed 14 Aug 202686,095$190K+17,781+26.0%
31 Mar 2023 – 30 Jun 2026
344045Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Tommy G. Thompson Company insiderDirector · last 23 Dec 202515 · 0
Cooper C. Collins Company insiderDirector · last 3 Nov 202510 · 1
Gail K. Naughton Company insiderDirector · last 3 Nov 20250 · 1
Marlan D. Walker Company insiderChief Executive Officer · last 3 Nov 20253 · 6
David Efraim Rosen Company insider10% owner · last 15 Nov 20235 · 0
Joseph Ziegler Company insiderPrincipal Financial Officer · last 17 Aug 20230 · 0
Michael C. Donegan Company insiderPrin. Fin. and Acctg. Officer · last 12 Apr 20230 · 7
Rubric Capital Management Lp Company insiderDirector, 10% owner, Other · last 30 Dec 20223 · 1
Brian Bernick Company insiderCo-Chief Executive Officer · last 9 Dec 20222 · 28
Mark A. Glickman Company insiderCo-Chief Executive Officer · last 6 Dec 20220 · 1
Angus C. Russell Company insiderDirector · last 29 Sep 20225 · 0
Jules A. Musing Company insiderDirector · last 29 Sep 20223 · 1

Same industry

MRNA ModernaLeading+168%
IOVA Iovance BiotherapeuticsLeading+134%
ABCL AbCellera BiologicsLeading+62%
ENTX Entera BioLeading+53%
HALO Halozyme TherapeuticsLeading+48%
XERS Xeris Biopharma HoldingsLeading+42%
XNCR XencorLeading+41%
HELP Helus PharmaLeading+37%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-145%
Return on capital employedFY 2025 · to 31 Dec 2025-13.4%
Share count trendFY 2025 · to 30 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.5M

Analyst forecasts

No analyst forecasts yet.